{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:55:00Z","timestamp":1791287700479,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pulm. circ."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    This study quantified the recent real\u2010world burden of pulmonary arterial hypertension (PAH) using US real\u2010world data. Adults (18+) with treated PAH were identified from the MarketScan Commercial\/Medicare Databases using a claims\u2010based algorithm requiring pulmonary hypertension diagnosis, PAH\u2010specific treatment, and right heart catheterization from January 1, 2017 to August 31, 2024 (earliest treatment claim\u2009=\u2009index). Patients were followed for \u2265 30\u2009days post\u2010index, overall and stratified by payer and by treatment categories. Subsets of PAH\u2010hospitalized and newly treated patients were also analyzed. Measures included demographics, clinical characteristics, all\u2010cause healthcare utilization\/costs, PAH\u2010related hospitalization costs\/characteristics, and all\u2010cause mortality. Overall, 2712 treated PAH patients were included (mean age 61.8\u2009years, 68.9% female, 57.9% commercial insurance). During mean 2.2\u2009years of follow\u2010up, mean (median) per\u2010patient\u2010per\u2010year all\u2010cause healthcare costs were $302,014 ($210,888) for commercially\u2010insured patients and $200,581 ($147,706) for Medicare patients. Over half (56.2%) of patients had \u2265 1 all\u2010cause hospitalization, 44.9% had \u2265 1 PAH\u2010related hospitalization, and 31.0% were hospitalized for \u2265 1 complication (thrombosis [14.1%], hemorrhage [12.5%], sepsis [14.9%]). Among the PAH\u2010hospitalized subset (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20091079), median time to re\u2010hospitalization was 1.2\u2009years. The mean (median) cost per PAH\u2010related hospitalization was $89,799 ($30,224) for commercially\u2010insured and $37,288 ($15,733) for Medicare patients, and 57.2% of hospitalizations required an ICU stay. Among the newly treated subset (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20092072), 9.7%, 18.6%, and 25.2% of patients died within 1, 2, and 3\u2009years after treatment initiation. Despite recent therapeutic advancements, PAH patients continue to have a substantial clinical and economic burden. These findings highlight ongoing unmet need and underscore the importance of continued monitoring of disease burden as PAH therapies evolve.\n                  <\/jats:p>","DOI":"10.1002\/pul2.70414","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:30:19Z","timestamp":1791286219000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Economic, Hospitalization, and Mortality Burden Among Pulmonary Arterial Hypertension Patients: A Real\u2010World US Claims Data Analysis"],"prefix":"10.1002","volume":"16","author":[{"given":"Ashwin","family":"Ravichandran","sequence":"first","affiliation":[{"name":"Ascension St. Vincent Heart Center Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0535-672X","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Beaudet","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Allschwil Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2310-3793","authenticated-orcid":false,"given":"David","family":"Lopez","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1115-0672","authenticated-orcid":false,"given":"Carolyn R.","family":"Lew","sequence":"additional","affiliation":[{"name":"Merative Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Varker","sequence":"additional","affiliation":[{"name":"Merative Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-8090","authenticated-orcid":false,"given":"Michelle","family":"Jerry","sequence":"additional","affiliation":[{"name":"Merative Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7103-0560","authenticated-orcid":false,"given":"Akshay","family":"Muralidhar","sequence":"additional","affiliation":[{"name":"Arizona Pulmonary Specialists Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.540"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019877157"},{"issue":"3","key":"e_1_2_12_4_1","first-page":"47","article-title":"Characterizing Pulmonary Hypertension\u2010Related Hospitalization Costs Among Medicare Advantage or Commercially Insured Patients With Pulmonary Arterial Hypertension: A Retrospective Database Study","volume":"21","author":"Burke J. P.","year":"2015","journal-title":"American Journal of Managed Care"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.17391"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01427-2"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1363049"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0338335"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202302-0327SO"},{"key":"e_1_2_12_11_1","unstructured":"\u201cU.S. FDA Approves OPSYNVI (Macitentan and Tadalafil) as the First and Only Once\u2010Daily Single\u2010Tablet Combination Therapy for Patients With Pulmonary Arterial Hypertension (PAH) [Press Release] \u201d Johnson & Johnson 2024 accessed March 26 2025 https:\/\/www.jnj.com\/media-center\/press-releases\/u-s-fda-approves-opsynvi-macitentan-and-tadalafil-as-the-first-and-only-once-daily-single-tablet-combination-therapy-for-patients-with-pulmonary-arterial-hypertension-pah."},{"key":"e_1_2_12_12_1","unstructured":"\u201cFDA Approves Merck's WINREVAIR (sotatercept\u2010csrk) A First\u2010in\u2010Class Treatment for Adults With Pulmonary Arterial Hypertension (PAH WHO Group 1) [Press Release] \u201d Merck 2024 accessed March 26 2025 https:\/\/www.merck.com\/news\/fda-approves-mercks-winrevair-sotatercept-csrk-a-first-in-class-treatment-for-adults-with-pulmonary-arterial-hypertension-pah-who-group-1\/."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01325-2024"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508170"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01889-2018"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.11.030"},{"key":"e_1_2_12_17_1","unstructured":"\u201cRevatio Package Insert \u201d Pfizer 2014 accessed March 26 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021845s011 022473s004 0203109s002lbl.pdf."},{"key":"e_1_2_12_18_1","unstructured":"\u201cALYQ Package Insert \u201d Teva Pharmaceuticals 2022 accessed March 26 2025 https:\/\/www.accessdata.fda.gov\/spl\/data\/ec193ea7-dc76-303f-e053-2a95a90abf47\/ec193ea7-dc76-303f-e053-2a95a90abf47.xml."},{"key":"e_1_2_12_19_1","unstructured":"\u201cAdcirca Package Insert \u201d Eli Lilly and Company 2020 accessed March 26 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022332Orig1s011lbl.pdf."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5204"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0055-2016"},{"key":"e_1_2_12_22_1","unstructured":"\u201cSildenafil Citrate (Generic for Revatio) \u201d accessed March 26 2025 https:\/\/www.costplusdrugs.com\/medications\/sildenafilcitrate-20mg-tablet\/."},{"key":"e_1_2_12_23_1","unstructured":"D.McDermott J.Hudman D.Cotliar et al. \u201cHow Costly Are Common Health Services in the United States? \u201d 2020 accessed March 26 2025 https:\/\/www.healthsystemtracker.org\/chart-collection\/how-costly-are-common-health-services-in-the-united-states\/."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12333"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2021.07.029"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.06.036"},{"key":"e_1_2_12_27_1","volume-title":"StatPearls","author":"Zeijia A. G.","year":"2024"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61050922"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024969"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00130408"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcac.2016.06.003"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106336"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03468-1"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217719250"}],"container-title":["Pulmonary Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pul2.70414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pul2.70414","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pul2.70414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:30:29Z","timestamp":1791286229000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pul2.70414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/pul2.70414"],"URL":"https:\/\/doi.org\/10.1002\/pul2.70414","archive":["Portico"],"relation":{},"ISSN":["2045-8940","2045-8940"],"issn-type":[{"value":"2045-8940","type":"print"},{"value":"2045-8940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70414"}}